Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1...
Read moreLatest News
Category: News
Telix Appoints David Gill as Non-Executive Director
Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill...
Read more
You’re Not Alone
News,
Liz Leff was diagnosed with clear cell renal cell carcinoma (ccRCC) in 2014. The experience shaped everything that followed, including a career in patient advocacy that eventually brought her to...
Read more
Live Your Life
News,
Maggie Valdes Butera’s husband Brandon was diagnosed with kidney cancer in 2021 at the age of 26. He passed away in 2024. We spoke to Maggie about their journey together,...
Read more
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Telix today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational...
Read more
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Telix today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has...
Read more
Investor Education Webinar: The Future of Prostate Imaging: What do physicians want?
Telix invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate...
Read more
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
Telix today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry, defining the potential prognostic value of PSMA-PET imaging through artificial intelligence...
Read more
TLX591-Tx: Development overview and data highlights
News,
As a resource for analysts and investors, Telix has published a clinical data summary for TLX591-Tx (lutetium-177 rosopatamab tetraxetan), its investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC)....
Read more
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix today announces its financial results for the year ended December 31,...
Read more